This stock keeps climbing the stairs higher

Look this up before it is too late                                                                                                                                                                                                                                                                                                                                                                                                                 October 12, 2023 This stock keeps climbing the stairs higher *Sponsored by Sica Media The markets continue to chug higher, and are pulling lots of stocks higher with it. My favorite stock today is having a great session as well: MAIA Biotechnology, Inc. (NYSE: MAIA) The market seems to be loving the [news]( MAIA dropped this morning showing positive data on one of the most aggressive tumors affecting the central nervous system in children. MAIA has been on fire the last few weeks, and I see no reason why that should change anytime soon. The company keeps delivering strong news, is led by excellent leadership that has shown their support by actively making stock purchases (as well as an announced stock buyback program), and analyst coverage that forecasts a nearly 500% potential target from current prices. Most important to me is simply the price action. I always say that economics and news are great, but it all comes down to how the market responds to the stock. With MAIA, we continue to see a very positive reaction from the market to news and the dips have been bought up over the last few weeks. With the difficult environment we have been through, MAIA has been a stellar outperformer. As a refresher, MAIA is a Chicago-based immuno-oncology company that was in a steady drawdown since January, but two weeks ago, it took a turn up, and a steady barrage of great news has continued to propel it higher: That’s often how charts for these clinical-stage biotechs look. Early investors lose patience or grow anxious as trials draw on and cash-on-hand draws down, then news hits and BAM! We’re off to the races 🏇. As you’ll see, any anxiety investors had should be considerably soothed based on this spate of news. And for our purposes, it looks like this may just be the beginning of a much larger run… Here are the big things that jumped out from my research: Lead Asset Progressing The biggest news, in my view, was what MAIA observers had been eager to hear for months. Back in July, Seeking Alpha published [an analysis]( by “Biotech Beast” (I’m trying to convince my wife to call me that 😂), who said “I consider MAIA a buy as I expect the upcoming catalyst that is another update on the THIO-101 trial in the fall (Q3'23 to Q4'23) to result in a rally.” Well, just Tuesday we got another bombshell [headline](: THIO — the company’s lead asset — is an agent that targets the telomeres of cancer cells, “leading to ‘uncapping’ of the chromosome ends and thus resulting in rapid tumor cell death” according to the company’s [website](. Source: [MAIA Corporate Presentation](, June 2023 The news was that among the 49 early enrollees in THIO’s Phase II trial, “37 already completed at least 1 post baseline assessment.” This “encouraging efficacy observed in dosed patients is prompting physicians to speed up trial enrollment even further.” The week earlier, the company [announced]( FDA approval of its Investigational New Drug (IND) application for THIO. This will allow the company to expand its Phase II trial — which was already taking place in Australia and Europe — into the US, and should also help speed along enrollment. Back on October 10, we also [learned]( that THIO “showed highly potent anticancer activity in gliomas, an aggressive type of brain tumor.” “These encouraging results further highlight THIO’s excellent anti-cancer activity across several cancer indications," said MAIA’s CEO Vlad Vitoc, M.D. Insider Confidence Is High One of the biggest things to look for when surveying a clinical-stage biotech is positive insider sentiment. Obviously these companies will put on a smile in their press releases and corporate presentations, but when it comes down to it, will they put their own money where their mouths are? Well clearly, the [top folks]( at MAIA are true believers: Over the last year, company insiders bought shares 79 times and didn’t have a single sell reported, even during the post-January drawdown. I mean, in this market, all I do is hear about insiders dumping shares. MAIA insiders are actually putting more skin in the game with shareholders. This tells me the people who would know best believe in the efficacy of their drug pipeline and believe that at least some products will pan out. Another very strong sign of insider confidence was the [announcement]( on September 28 (two days after the stock began its reversal) of an $800,000 share repurchase program that the company can exercise through September 2024. $800k is nothing to sneeze at for a company with a miniscule market cap like MAIA! But more important than what the program could do to the share price is that it signals MAIA isn’t likely to do a capital raise right now, and that executives feel comfortable enough with their cash reserves that they are choosing to add value to shareholders by purchasing their own stock. Again, all of this tells me that the “people who would know” see a bright future for MAIA. Bullish Sentiment Abounds But MAIA executives aren’t the only ones who seem bullish on the stock. Earlier, I quoted the incredibly-named Biotech Beast of Seeking Alpha who considered the company a “buy” in July. In the [same article](, he outlined his reservations: The risks of any long in MAIA are several fold . . . . Firstly, subsequent data from THIO-101 could disappoint, secondly, MAIA could fail to raise additional funds leading to concerns over cash and thirdly, delays in enrollment could cause the stock to trade down. With the benefit of hindsight, I think we can say all those concerns have been mitigated at the very least. While Mr. Beast’s analysis didn’t make it to [TipRanks](, I was able to find that an analyst from Noble Financial reiterated a “buy” rating with a whopping $14.00 price target for MAIA — which would make it a five-bagger opportunity from its current price of $2.32. Over at Yahoo! Finance, all signs are flashing green: Yahoo! has even given MAIA a near-perfect score when compared to others in its sector: Clearly, others are just as excited about MAIA as I am — and as I hope you are reading this. Wrapping Up I mentioned to you on Tuesday that the “go/no go” algorithm is the single-best computer-generated indicator I look to, as it combines over a dozen different momentum indicators to get a read on where a stock is going. Here’s the readout on MAIA: You can see the big breakout starting on 9/28. It has consolidated from there, but is now threatening to break the resistance level and possibly continue its uptrend. That’s why I think now is a critical time to take a look at this stock. The news about the success of the company’s leading asset is hot off the presses, and investors are just coming to terms with it. Clearly, investors see promise in MAIA’s potentially groundbreaking therapeutics, and this latest batch of news will only help confirm that. I think the 90% rally we saw over the last two weeks could likely be in the early innings, and looking at the price action from yesterday, I think this is an urgent opportunity to get in at the right price for what could be a powerhouse rally. There is a big move coming for MAIA (one way or another) very soon – be on the lookout for it! That’s what I think. As always, you must do your own research to see if you agree. Google “MAIA”, study the chart, read the financials… do all your due diligence and have a gameplan that fits your personal risk profile. But do so soon, because I think this one could be ready to explode 🧨. To Your Success *This investment involves substantial risk. Please see full disclosure below, and detailed discussion of risks and atypical results. Full Disclaimer Questions or concerns about our products? Email Support@ragingbull.com © Copyright 2022, RagingBull DISCLAIMER: To more fully understand any Ragingbull.com, LLC ("RagingBull") subscription, website, application or other service ("Services"), please review our full disclaimer located at [(. FOR EDUCATIONAL AND INFORMATION PURPOSES ONLY; NOT INVESTMENT ADVICE. Any RagingBull Service offered is for educational and informational purposes only and should NOT be construed as a securities-related offer or solicitation, or be relied upon as personalized investment advice. RagingBull strongly recommends you consult a licensed or registered professional before making any investment decision. RESULTS PRESENTED NOT TYPICAL OR VERIFIED. RagingBull Services may contain information regarding the historical trading performance of RagingBull owners or employees, and/or testimonials of non-employees depicting profitability that are believed to be true based on the representations of the persons voluntarily providing the testimonial. However, subscribers' trading results have NOT been tracked or verified and past performance is not necessarily indicative of future results, and the results presented in this communication are NOT TYPICAL. Actual results will vary widely given a variety of factors such as experience, skill, risk mitigation practices, market dynamics and the amount of capital deployed. Investing in securities is speculative and carries a high degree of risk; you may lose some, all, or possibly more than your original investment. RAGINGBULL IS NOT AN INVESTMENT ADVISOR OR REGISTERED BROKER. Neither RagingBull nor any of its owners or employees is registered as a securities broker-dealer, broker, investment advisor (IA), or IA representative with the U.S. Securities and Exchange Commission, any state securities regulatory authority, or any self-regulatory organization. WE MAY HOLD SECURITIES DISCUSSED RagingBull has not been paid directly or indirectly by the issuer of any security mentioned in the Services except possibly by advertisers in this email. However, Ragingbull.com, LLC, its owners, and its employees may purchase, sell, or hold long or short positions in securities of the companies mentioned in this communication. If you have a current active subscription with Jason Bond Picks you will need to contact us here if you want to cancel your subscription. Opting out of emails does not remove you from your service at JasonBondPicks.com. In the event that any suit or action is instituted as a result of doing business with RagingBull.com, LLC and/or its affiliates or if any suit or action is necessary to enforce or interpret these Terms of Service, RagingBull.com, LLC shall be entitled to recover attorneys’ fees, costs and disbursements in addition to any other relief to which it may be entitled. Update your email preferences or unsubscribe [here]( © 2023 Jason Bond Picks 62 Calef Hwy. #233 Lee, NH 03861, United States of America